Revolutionary 5-In-1 Compound Shows Promise for Diabetes and Weight Loss
Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss
Ndtv
Image: Ndtv
Researchers have developed a groundbreaking 'five-in-one' compound that outperforms existing diabetes and obesity treatments like semaglutide. This innovative approach combines multiple biological pathways to enhance metabolism, offering a more effective solution for managing blood sugar and weight loss, as presented at the European Association for the Study of Diabetes Annual Meeting.
- 01The new 'five-in-one' compound integrates five distinct signaling pathways for improved diabetes and obesity treatment.
- 02This compound combines GLP-1 and GIP receptor agonists with lanifibranor, enhancing metabolic regulation.
- 03Early studies in mice indicate significant improvements in blood sugar levels and weight loss compared to current therapies.
- 04Current treatments primarily target appetite and insulin regulation, but the new compound addresses deeper metabolic dysfunction.
- 05The findings represent a significant step towards personalized and effective metabolic health solutions, though human trials are still needed.
Advertisement
In-Article Ad
A new 'five-in-one' experimental compound has been developed that shows potential to surpass existing diabetes and obesity treatments such as semaglutide. This innovative compound, presented by researcher Daniela Liskiewicz, PhD, at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting, integrates five distinct signaling pathways to regulate metabolism, offering a comprehensive approach to managing these complex conditions. The compound, termed a 'quintuple agonist,' combines GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists with lanifibranor, which activates three peroxisome proliferator-activated receptors (PPAR-alpha, PPAR-delta, and PPAR-gamma). This multi-target strategy has shown remarkable efficacy in improving blood sugar levels and reducing body weight in obese, diabetic mice, indicating a significant advancement over current therapies that primarily focus on appetite and insulin regulation. The synergistic nature of the five-in-one compound allows for better metabolic control, addressing the root causes of obesity and diabetes rather than merely masking symptoms. However, while these results are promising, they are preliminary, and extensive human clinical trials will be necessary to confirm safety and effectiveness before this compound can be made available for public use.
Advertisement
In-Article Ad
This new compound could lead to more effective treatments for diabetes and obesity, potentially improving the quality of life for millions of patients worldwide.
Advertisement
In-Article Ad
Reader Poll
Do you believe multi-targeted therapies will improve diabetes and obesity treatment outcomes?
Connecting to poll...
Read the original article
Visit the source for the complete story.



